European Commission authorises second safe and effective vaccine against COVID-19
The European Commission yesterday granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Moderna, the second COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.
The President of the European Commission, Ursula von der Leyen, yesterday said:
“We are providing more COVID-19 vaccines for Europeans. With the Moderna vaccine, the second one now authorised in the EU, we will have a further 160 million doses. And more vaccines will come. Europe has secured up to two billion doses of potential COVID-19 vaccines. We'll have more than enough safe and effective vaccines for protecting all Europeans.”
Stella Kyriakides, Commissioner for Health and Food Safety, yesterday said:
“We are all in this together and united. This is why we have negotiated the broadest vaccine portfolio in the world for all our Member States. Today we are authorising a second safe and effective vaccine from Moderna, which together with BioNTech-Pfizer, will ensure that 460 million doses will be rolled out with increasing speed in the EU, and more will come. Member States have to ensure that the pace of vaccinations follows suit. Our efforts will not stop until vaccines are available for everyone in the EU.”
Moderna submitted on 30 November 2020 an application for marketing authorisation to EMA, which had already started a rolling review of the data in November. Thanks to this rolling review, EMA has been assessing the quality, safety and efficacy of the vaccine as data has become available. EMA's human medicines committee (CHMP) has thoroughly assessed the data and recommended by consensus that a formal conditional marketing authorisation is granted. A conditional marketing authorisation is one of EU's regulatory mechanisms for facilitating early access to medicines that fulfil an unmet medical need, including in emergency situations such as the current pandemic.
On the basis of EMA's positive opinion, the Commission has verified all the elements supporting the marketing authorisation and consulted Member States before granting the conditional market authorisation.
The Moderna vaccine is based on messenger RNA (mRNA). mRNA plays a fundamental role in biology, transferring instructions from DNA to the cells' protein making machinery. In an mRNA vaccine, these instructions produce harmless fragments of the virus, which the human body uses to build an immune response to prevent or fight disease. When a person is given the vaccine, their cells will read the genetic instructions and produce a spike protein, a protein on the outer surface of the virus which it uses to enter the body's cells and cause disease. The person's immune system will then treat this protein as foreign and produce natural defences – antibodies and T cells – against it.
Latest News from
Human rights breaches in Hong Kong, Turkey and Vietnam22/01/2021 16:33:00
On Thursday, Parliament adopted three resolutions taking stock of the human rights situation in Hong Kong, Turkey and Vietnam.
EU tax haven blacklist is not catching the worst offenders22/01/2021 15:25:00
MEPs adopted a resolution pushing for the system used to draw up the EU list of tax havens to be changed, as it is currently “confusing and ineffective”.
Council agrees on strengthening the use of rapid antigen tests and on the mutual recognition of COVID-19 test results22/01/2021 14:33:00
Member states yesterday unanimously agreed, by written procedure, on a Council recommendation setting a common framework for the use of rapid antigen tests and the mutual recognition of COVID-19 test results across the EU.
Commission welcomes agreement on additional financial support for the most deprived under REACT-EU22/01/2021 13:25:00
The European Parliament has voted through the political agreement reached by the co-legislators on the Commission's proposal to provide more funds to support the most deprived in Europe in the recovery phase.
Parliament demands significantly tighter EU sanctions against Russia22/01/2021 12:38:00
Following the recent imprisonment of Alexei Navalny, MEPs call on EU countries to significantly strengthen sanctions against Russia.
Foreign and security policy: MEPs call for unity and strategic autonomy22/01/2021 11:33:00
The COVID-19 pandemic is a wake-up call for Europe, which needs a stronger, more united and more assertive foreign and security policy, MEPs highlighted on Wednesday.
Human rights and COVID-19: MEPs denounce measures taken by authoritarian regimes22/01/2021 10:38:00
Parliament is deeply concerned that many authoritarian regimes around the world have used the pandemic to repress civil society and critical voices.
Guidelines for military and non-military use of Artificial Intelligence22/01/2021 09:25:00
Artificial Intelligence must be subject to human control, allowing humans to correct or disable it in case of unforeseen behaviour, say MEPs.
Joint Statement by Executive Vice-President Frans Timmermans and High Representative/Vice-President Josep Borrell on the United States re-joining the Paris Agreement21/01/2021 16:33:00
Joint Statement given yesterday by Executive Vice-President Frans Timmermans and High Representative/Vice-President Josep Borrell on the United States re-joining the Paris Agreement.